Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)

NCT04196231 on ClinicalTrials.gov · last registry update 2020-10-22

An unusually large phase 4: 258 participants, more than double the 75 typical for the stage. The sponsor logged completion for 30 September 2020. Primary outcome, as filed: Hba1c change. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University of Campania Luigi Vanvitelli
Sponsor type: Other
Enrollment: 258
Started: 2019-11-27
Primary completion: 2020-09-30 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Hba1c change

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.